Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2017 3
2019 1
2020 1
2021 5
2022 5
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Wu B, Sternheim N, Agarwal P, Suchomel J, Vadhavkar S, Bruno R, Ballinger M, Bernaards CA, Chan P, Ruppel J, Jin J, Girish S, Joshi A, Quarmby V. Wu B, et al. Among authors: vadhavkar s. Clin Transl Sci. 2022 Jan;15(1):130-140. doi: 10.1111/cts.13127. Epub 2021 Aug 25. Clin Transl Sci. 2022. PMID: 34432389 Free PMC article.
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.
Zhu R, Chen H, Galanter J, She G, Cai F, Durk MR, Zou Y, Chen L, Kenny JR, Vadhavkar S, Warren S, Taylor G, Hwang O, Eliahu A, Wynne C, Owen R. Zhu R, et al. Among authors: vadhavkar s. Clin Transl Sci. 2022 May;15(5):1225-1237. doi: 10.1111/cts.13240. Epub 2022 Feb 26. Clin Transl Sci. 2022. PMID: 35157370 Free PMC article. Clinical Trial.
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Samineni D, Gibiansky L, Wang B, Vadhavkar S, Rajwanshi R, Tandon M, Sinha A, Al-Sawaf O, Fischer K, Hallek M, Salem AH, Li C, Miles D. Samineni D, et al. Among authors: vadhavkar s. Adv Ther. 2022 Aug;39(8):3635-3653. doi: 10.1007/s12325-022-02170-w. Epub 2022 Jun 16. Adv Ther. 2022. PMID: 35708885 Free PMC article. Clinical Trial.
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
Chan P, Marchand M, Yoshida K, Vadhavkar S, Wang N, Lin A, Wu B, Ballinger M, Sternheim N, Jin JY, Bruno R. Chan P, et al. Among authors: vadhavkar s. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1171-1182. doi: 10.1002/psp4.12686. Epub 2021 Aug 4. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34270868 Free PMC article.
20 results